Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)   MAY 2014 , Volume 8 , Number 3; Page(s) 201 To 206.
 
Paper: 

LOVASTATIN FOR REDUCTION OF LEPTIN IN NONDIALYSIS PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY

 
 
Author(s):  GHOLAMIN SHARAREH*, RAZAVI SEYED MOSTAFA, TAGHAVI GARMESTANI SEYED MEGHDAD, GHORBANIHAGHJO AMIR, RASHTCHIZADEH NADEREH, SAFA JAVID, VATANKHAH AMIR MANSOUR, AZIZI TABASSOM, ARGANI HASSAN
 
* INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE, LORRY I. LOKEY STEM CELL RESEARCH BUILDING, STANFORD, CA 94305, USA
 
Abstract: 
Introduction. Diabetic Nephropathy (DN) is one of the main complications of diabetes mellitus, mostly ending to end-stage renal disease. Leptin and C-reactive protein (CRP), as inflammatory markers implicated in the progression of DN, increase in diabetes mellitus, while transferrin and albumin, as members of anti-oxidant defense mechanism, are found to decline.Materials and Methods. In a controlled clinical trial, 65 patients with type 2 DN were assigned to receive lovastatin or placebo, for 3 months, to assess statins’ impact on serum levels of leptin, CRP, transferrin, albumin, and lipid profile.Results. Serum levels of CRP (3.52±4.16 mg/dL to 2.84±3.06 mg/dL, P= .02), leptin (10.78±8.30 mg/dL to 7.80±5.41 mg/dL, P= .006), low-density lipoprotein cholesterol (116.16±46.54 mg/dL to 85.46±29.22 mg/dL, P< .001), and total cholesterol (199.00±43.33 mg/dL to 164.67±35.19 mg/dL, P< .001) were lowered after lovastatin therapy. Mean serum level of high-density lipoprotein cholesterol increased (40.00 mg/dL to 42.80 mg/dL, P= .005) after the treatment. Lovastatin had no significant effect on albumin and transferrin. Placebo did not change any of the parameters after 3 months.Conclusions. The effect of statins on the inflammatory markers involved in the development of DN is a new approach to evidence supporting the pleiotropic effect of this drug group.
 
Keyword(s): LOVASTATIN, LEPTIN, TRANSFERRIN, ALBUMIN, DIABETIC NEPHROPATHY
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

GHOLAMIN, S., & RAZAVI, S., & TAGHAVI GARMESTANI, S., & GHORBANIHAGHJO, A., & RASHTCHIZADEH, N., & SAFA, J., & VATANKHAH, A., & AZIZI, T., & ARGANI, H. (2014). LOVASTATIN FOR REDUCTION OF LEPTIN IN NONDIALYSIS PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), 8(3), 201-206. https://www.sid.ir/en/journal/ViewPaper.aspx?id=408850



Vancouver: Copy

GHOLAMIN SHARAREH, RAZAVI SEYED MOSTAFA, TAGHAVI GARMESTANI SEYED MEGHDAD, GHORBANIHAGHJO AMIR, RASHTCHIZADEH NADEREH, SAFA JAVID, VATANKHAH AMIR MANSOUR, AZIZI TABASSOM, ARGANI HASSAN. LOVASTATIN FOR REDUCTION OF LEPTIN IN NONDIALYSIS PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD). 2014 [cited 2021December06];8(3):201-206. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=408850



IEEE: Copy

GHOLAMIN, S., RAZAVI, S., TAGHAVI GARMESTANI, S., GHORBANIHAGHJO, A., RASHTCHIZADEH, N., SAFA, J., VATANKHAH, A., AZIZI, T., ARGANI, H., 2014. LOVASTATIN FOR REDUCTION OF LEPTIN IN NONDIALYSIS PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), [online] 8(3), pp.201-206. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=408850.



 
  pdf-File
Yearly Visit 43
 
 
Latest on Blog
Enter SID Blog